Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
AntiRadical Therapeutics LLC
Bayer AG
Boehringer Ingelheim Intertiol GmbH
Cyclerion Therapeutics Inc
Ebelle Pharmaceuticals Inc
NicOx SA
Novan Inc
Novartis AG
Novoteris LLC
Toa Eiyo Ltd
Topadur Pharma AG
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
A-8R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1237592 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-546544 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-703704 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxyurea - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AntiRadical Therapeutics LLC, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Cyclerion Therapeutics Inc, H2 2019
Pipeline by Ebelle Pharmaceuticals Inc, H2 2019
Pipeline by NicOx SA, H2 2019
Pipeline by Novan Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Novoteris LLC, H2 2019
Pipeline by Toa Eiyo Ltd, H2 2019
Pipeline by Topadur Pharma AG, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Discontinued Products, H2 2019